Writing an Investigational New Drug (IND) application is a major hurdle for drug developers. It can take a team of specialists three to four months, and mistakes can trigger protocol amendments or clinical holds. In June, we started working with Population Health Partners (PHP) to leverage specialized Kosmos Clinical Protocol Design (“CPD”) and Kosmos Regulatory Authoring (“RA”) products to support PHP’s process of IND preparation. Since then, specially trained Kosmos products produced a first acceptable draft of the Nonclinical Overview in 4.2 hours, against 100 hours of expert time, flagged an error that roughly fifteen human reviewers missed, and authored 70% of the text in a Pre-IND Briefing Meeting Request submitted to FDA. PHP is now bringing Kosmos products to a second program and expects to complete IND preparation in as little as 1 month, instead of the 4 month industry standard. PHP's experts can spend their time reviewing and deciding, not just drafting. The time recovered by Kosmos products means that drugs could make their way to patients faster.

Kosmos can now read @NaturePortfolio! Today we're announcing a subscription agreement with @SpringerNature that brings licensed content from specialist journals across the Nature Portfolio directly into Kosmos. When Kosmos generates a hypothesis or evaluates a target, it can now pull directly from Springer Nature journals, linked to the Version of Record so it's iterating on current, correct science. This is the first of several content partnerships we plan to announce, because better-sourced literature makes for a faster path from discovery to development.

We're honored to be named to @BostonGlobe's inaugural 'Next in Medicine' list, which recognizes companies using research and technology to shape the future of patient care. At Edison Scientific, that means building Kosmos, an AI scientist capable of compressing the months long, iterative work of R&D to one day. From discovery, to development, to the clinic, Kosmos is driving scientific advancement across domains.

Join the Edison team at our AI Biotech Block Party, co-hosted with @multiplylabs! The evening will include a fireside chat with @FredParietti, CEO of Multiply Labs, and @andrewwhite01, CTO of Edison, on the future of AI across drug discovery, development, and manufacturing. Plus food, drinks, lab tours, and demos!

Introducing BixBench3, our latest eval for language models in science and the first eval to measure the ability of models to produce the analyses underpinning entire biology papers from raw data. BixBench3 evaluates 13 frontier models on 20 paper-derived tasks, using datasets up to 241 GB. Each task mirrors how scientists often use agents today: setting a research objective and designing a methodological plan, then delegating implementation to the agent. The best model reproduced 48% of the requested artifacts on average. Agents are starting to approach research study-scale capabilities, but there is still plenty of work to do.

Edison is officially in New York! We opened the doors to our new SoHo office this week, and we’re so excited to give our rapidly growing NYC team a place to call home. We’re hiring in New York, San Francisco, and beyond. Come join us!